The expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), and Ki67 is commonly employed in clinical practice to categorize breast cancer subtypes, guiding the selection of appropriate treatment methods. This evidence concerns the gene MKI67 and breast cancer.